Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP. Teng YKO, et al. Among authors: furie ra. BMJ Open. 2019 Mar 20;9(3):e025687. doi: 10.1136/bmjopen-2018-025687. BMJ Open. 2019. PMID: 30898822 Free PMC article.
Treatment of systemic lupus erythematosus with LJP 394.
Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Liebling MR, Hudson NP, Berner CM, Coutts S, de Haan HA. Furie RA, et al. J Rheumatol. 2001 Feb;28(2):257-65. J Rheumatol. 2001. PMID: 11246659 Clinical Trial.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. Furie R, et al. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups. Wallace DJ, et al. Among authors: furie r. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4. Lupus. 2013. PMID: 23213069 Clinical Trial.
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group. Ginzler EM, et al. Among authors: furie ra. J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1. J Rheumatol. 2014. PMID: 24187095 Free article. Clinical Trial.
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study. Furie RA, et al. Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19. Ann Rheum Dis. 2015. PMID: 24748629 Clinical Trial.
Treatment Algorithms in Systemic Lupus Erythematosus.
Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inanç M, Rothfield NF, Nash PT, Furie RA, Senécal JL, Chandran V, Burgos-Vargas R, Ramsey-Goldman R, Pope JE. Muangchan C, et al. Among authors: furie ra. Arthritis Care Res (Hoboken). 2015 Sep;67(9):1237-1245. doi: 10.1002/acr.22589. Arthritis Care Res (Hoboken). 2015. PMID: 25777803 Free article.
181 results